NBDF’s Pathway to Cures Launches Spark Biomedical’s LUNA Trial to Explore Non-Drug Treatment for Heavy Menstrual Bleeding
For many women and adolescent girls living with inherited bleeding disorders, heavy menstrual bleeding (HMB) remains one of the most physically and emotionally burdensome symptoms—yet it is often overlooked in both diagnosis and treatment. Data from the National Bleeding Disorders Foundation highlight the scale of the challenge: nearly half of affected individuals report missing school or work due to excessive menstrual bleeding. Despite its prevalence and impact, HMB continues to be under-recognized, leaving patients with limited and often suboptimal treatment options.
In response to this unmet need, a new Phase II clinical study—known as the LUNA Trial—is now enrolling participants across the United States. The trial is investigating a novel, drug-free approach to managing HMB using transcutaneous auricular neurostimulation, a wearable technology designed to modulate the nervous system through stimulation of specific areas of the ear. This innovative method represents a potential shift away from traditional pharmaceutical treatments, offering a non-invasive alternative that could significantly improve patient outcomes and quality of life.
The study is being conducted by Spark Biomedical, a company focused on developing bioelectronic therapies. Spark Biomedical is part of the portfolio of Pathway to Cures, an initiative dedicated to accelerating the development of new treatment options for individuals with bleeding disorders. Through this collaboration, the trial reflects a broader commitment to advancing patient-centered innovation in an area that has historically received limited attention.
The LUNA Trial is designed as a randomized, double-blind, sham-controlled Phase II study, enrolling approximately 80 participants. It includes both adolescents aged 14 to 21 and adults aged 22 to 45 who experience heavy menstrual bleeding without a known structural cause. Importantly, the study also includes individuals diagnosed with von Willebrand disease, the most common inherited bleeding disorder, which frequently presents with HMB as a primary symptom.
One of the distinguishing features of the trial is its decentralized design. Unlike traditional clinical studies that require participants to travel to specific research sites, this approach allows individuals to enroll and participate remotely from multiple locations. This model reduces many of the logistical barriers that often limit participation in clinical research, such as travel time, geographic constraints, and scheduling challenges. By making the study more accessible, the decentralized format aims to increase diversity among participants and ensure that findings are more representative of real-world patient populations.
The core technology being evaluated—transcutaneous auricular neurostimulation—works by delivering mild electrical stimulation to specific nerve pathways in the ear. These pathways are connected to broader neural networks that influence pain perception, inflammation, and physiological regulation. By targeting these systems, the therapy aims to reduce menstrual blood loss and alleviate associated symptoms without the use of drugs. This approach could be particularly beneficial for patients who cannot tolerate or prefer to avoid hormonal or other pharmacological treatments.
The primary endpoint of the LUNA Trial is to determine the proportion of participants who achieve a clinically meaningful reduction in menstrual blood loss compared to their baseline levels. In addition to this primary measure, the study will evaluate several secondary outcomes, including reductions in menstrual cramp pain, improvements in overall symptom burden, and enhancements in quality of life. These endpoints reflect a holistic approach to patient care, recognizing that effective treatment must address not only the physical aspects of HMB but also its broader impact on daily functioning and well-being.
The trial is being conducted in collaboration with leading academic institutions, including Oregon Health & Science University, University of Michigan, and Yale University. These partnerships bring together expertise in clinical research, women’s health, and bleeding disorders, ensuring rigorous study design and execution.
Funding for the LUNA Trial is being provided by Wellcome Leap through its “Missed Vital Sign” program. This initiative seeks to elevate menstrual health as a critical indicator of overall health, including mental well-being. By supporting research that addresses gaps in understanding and treatment, the program aims to transform how menstrual health is perceived and managed within healthcare systems.
The importance of this work cannot be overstated. Heavy menstrual bleeding is not only a medical issue but also a social and economic one. For many patients, it leads to missed educational and professional opportunities, reduced productivity, and diminished quality of life. Yet, despite these impacts, it is often dismissed as a normal or unavoidable aspect of living with a bleeding disorder. The LUNA Trial challenges this perception by focusing on innovative solutions that prioritize patient needs and experiences.
Leaders involved in the study emphasize the significance of advancing non-pharmaceutical approaches. For patients with chronic conditions, long-term reliance on medications can be associated with side effects, adherence challenges, and varying levels of effectiveness. A wearable, non-invasive therapy could offer a more flexible and patient-friendly option, empowering individuals to manage their symptoms with greater control and convenience.
The trial also reflects a broader trend in healthcare toward bioelectronic medicine, a field that explores the use of targeted electrical stimulation to treat a range of conditions. By harnessing the body’s own neural pathways, these therapies have the potential to provide precise, personalized treatment with fewer systemic effects than traditional drugs. If successful, the LUNA Trial could pave the way for further applications of neurostimulation in women’s health and beyond.
Equally important is the role of organizations like Pathway to Cures in driving innovation. By combining philanthropic funding with venture capital principles, such initiatives can support high-risk, high-reward research that might otherwise struggle to secure traditional funding. This model enables the development of novel therapies that address unmet needs within specific patient communities.
As enrollment in the LUNA Trial continues, the study represents a hopeful step forward for women and girls living with bleeding disorders. By focusing on both clinical outcomes and patient experience, it seeks to redefine what effective treatment looks like in this space. Ultimately, the goal is not only to reduce symptoms but also to restore confidence, independence, and quality of life for those affected.
In a field where progress has often been slow, the introduction of innovative, patient-centered approaches like transcutaneous auricular neurostimulation signals a new era of possibility. Through collaboration, investment, and a commitment to addressing overlooked challenges, the LUNA Trial has the potential to make a meaningful difference in the lives of countless individuals who have long been underserved.
Source Link:https://www.businesswire.com/
